



E Zucca

Kontakt

E Zucca

Publikationen (5)

Moccia A, Mingrone W, Novak U, Pflieger C, Richter P, Rütli M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Hitz F. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. *Hematol Oncol* 2020; 39:196-204.

Hitz F, Mey U, Zucca E, Berardi Vilei S, Eckhardt K, Berthod G, Caspar C, Pabst T, Fischer N, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. *Ann Hematol* 2013; 92:1033-40.

Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. *Br J Cancer* 2010; 102:673-7.

Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. *J Clin Oncol* 2010; 28:4480-4484.

Hitz F, Ghielmini M, Zimmermann D, Bertoni F, Cogliatti S, Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. *Hematological oncology* 2009; 27:154-9.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch